The predictive value of RDS for the radiotherapy or chemical therapy in non-small cell lung cancer patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023707

Enrollment

Unknown

Registered

2019-06-08

Start date

2019-06-17

Completion date

Unknown

Last updated

2019-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Gold Standard:Clinical outcome

Index test:RDS

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged =18 years old; 2. Patients were diagnosed with primary non-small cell lung cancer (NSCLC) histologically or cytologically; 3. There are measurable lesions; 4. PS score 0-2; 5. The estimated survival time is more than 3 months; 6. The tissue was derived from the patient's tumor tissue with complete pathological diagnostic data including HE and IHC results.

Exclusion criteria

Exclusion criteria: 1. Patients received cytotoxic chemotherapy or radiotherapy within 28 days; 2. patients received allogeneic bone marrow transplantation or other organ transplantation; 3. Patients with incomplete medical records.

Design outcomes

Primary

Measure	Time frame
ORR;RDS;SEN, SPE, ACC, AUC of ROC;	—

Secondary

Measure	Time frame
PFS;TTP;	—

Countries

China

Contacts

Public ContactLiu Zhihua

Jiangxi Tumor Hospital

liuzhihua812@gmail.com+86 13807067275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026